Entrada Therapeutics Inc. Company Profile
NASDAQ: TRDAHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 7, 4:00 PM ET · Delayed 15 min
Entrada Therapeutics at a glance
Entrada Therapeutics Inc. (NASDAQ: TRDA) is a Biotechnology: Pharmaceutical Preparations company in the Health Care sector headquartered in Boston, MA. Entrada Therapeutics is led by Mr. Dipal Doshi and employs about 152 people. The company's shares have traded publicly since 2021.
At a market capitalization of $218.4 million, it is considered a small-cap company. Its SEC Central Index Key (CIK) is 0001689375, which identifies the company's filings on EDGAR.
Summary generated from market data by MetaCap's automated system. Methodology
What does Entrada Therapeutics do?
Entrada Therapeutics, Inc., is a clinical-stage biopharmaceutical company aiming to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle, therapeutic candidates are based on a novel therapeutic; a robust development portfolio of genetic medicines for the potential treatment of neuromuscular and inherited retinal diseases. Its preclinical product includes ENTR-601-44; ENTR-601-45; and VX-670. The company was formerly known as CycloPorters, Inc., and changed its name to Entrada Therapeutics, Inc., in October 2017. Entrada Therapeutics, Inc. was incorporated in 2016 and is headquartered in Boston, Massachusetts.
Business description based on the company's public filings.
Company information
- Legal name
- Entrada Therapeutics Inc.
- Ticker
- NASDAQ: TRDA
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Dipal Doshi
- Employees
- 152
- Headquarters
- One Design Center Place, Boston, MA, United States
- Phone
- 857 520 9158
- Website
- entradatx.com
- IPO year
- 2021
- Market cap
- $218.43M
- SEC CIK
- 0001689375
Companies similar to Entrada Therapeutics
| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| SIONSionna Therapeutics Inc. | 4.82 | +1.47% | $217.62M | vs TRDA |
| NATRNature's Sunshine Products Inc. | 12.59 | +0.40% | $221.53M | vs TRDA |
| KROSKeros Therapeutics Inc. | 11.21 | +1.82% | $222.26M | vs TRDA |
| EVMNEvommune Inc. | 6.22 | -5.90% | $225.74M | vs TRDA |
| GLSIGreenwich LifeSciences Inc. | 15.39 | -2.53% | $225.90M | vs TRDA |
| MGNXMacroGenics Inc. | 3.55 | -2.47% | $226.14M | vs TRDA |
| LYELLyell Immunopharma Inc. | 8.56 | -0.58% | $209.76M | vs TRDA |
| IFRXInflaRx N.V. | 1.56 | -1.27% | $229.89M | vs TRDA |